DOVATO FILM-COATED TABLET 50MG/300MG

GLAXOSMITHKLINE PTE LTD

GLAXOSMITHKLINE PTE LTD

Therapeutic

Prescription Only

TABLET, FILM COATED

**Dosage and Administration** Pharmaceutical form: Film-coated tablet Therapy should be initiated by a physician experienced in the management of HIV infection. _DOVATO_ can be taken with or without food. _DOVATO_ is a fixed-dose tablet and should not be prescribed for patients requiring dosage adjustments, such as those with creatinine clearance less than 30 mL/min. A separate preparation of dolutegravir ( _TIVICAY_) is available where a dose adjustment is required due to drug-drug interactions ( _see Interactions_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). For patients with integrase inhibitor resistance, _DOVATO_ is not recommended. In this case, the physician should refer to the dolutegravir ( _TIVICAY_) product information. **Adults and Adolescents** The recommended dose of _DOVATO_ in adults and adolescents weighing at least 40 kg is one tablet once daily. **Children** _DOVATO_ is not currently recommended for the treatment of children less than 12 years of age as the necessary dose adjustment cannot be made. Clinical data is currently not available for this combination. Physicians should refer to the individual product information for dolutegravir and lamivudine. **Elderly** There are limited data available on the use of dolutegravir and lamivudine in patients aged 65 years and over. However, there is no evidence that elderly patients require a different dose than younger adult patients ( _see Pharmacokinetics – Special Patient Populations_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). When treating elderly patients, consideration needs to be given to the greater frequency of decreased hepatic and renal function, haematological abnormalities, and concomitant medicinal products or disease. **Renal impairment** Whilst no dosage adjustment of dolutegravir is necessary in patients with renal impairment, a dose reduction of lamivudine is required due to decreased clearance. Therefore, _DOVATO_ is not recommended for use in patients with a creatinine clearance less than 30 mL/min ( _see Pharmacokinetics – Special Patient Populations_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). **Hepatic impairment** No dosage adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh grade A or B). No data are available for dolutegravir in patients with severe hepatic impairment (Child-Pugh grade C) ( _see Pharmacokinetics – Special Patient Populations_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).